Clinicaltrials.gov identifier: NCT04269642.

Study name	Effects of exenatide on motor function and the brain
Methods	Multi‐centre, randomised, double‐blind, placebo‐controlled, parallel comparison, phase IIa clinical study
Participants	Early stages of PD
Interventions	Intervention treatment 1: PT320 2.0mg injected subcutaneously once a week for 48 weeks Intervention treatment 2: PT320 2.5mg injected subcutaneously every two weeks for 48 weeks. (patients will be injected PT320 2.5 mg and placebo alternately once a week.) Comparison: placebo injected subcutaneously once a week for 48 weeks
Outcomes	Change of MDS‐UPDRS (Movement Disorder Society ‐Unified Parkinson's Disease Rating Scale ) part 3 score from baseline
Starting date	March 2020
Contact information	ihmhjoy@peptron.co.kr
Notes